Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zometa · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Test Group | EXPERIMENTAL | Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy. |
| Contorl Group | NO_INTERVENTION | Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy. |
| Name | Type | Description |
|---|---|---|
| Zometa (zoledronic acid) | DRUG | Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily |
Inclusion Criteria: * Age \>18, either sex * Histologically confirmed stage IV nasopharyngeal cancer * One bone metastasis at least confirmed by imaging * without chemotherapy or radiotherapy after bone metastasis * Life expectancy \> 6 M * ECOG \<= 2 * Adequate bone marrow reserve (WBC \> 3.5 x 10...
Zometa is a small molecule being studied for use in nasopharyngeal cancer, specifically for the treatment of bone metastases in patients with stage IV nasopharyngeal cancer. It is an investigational drug in this indication and is not approved for this use.
Zometa is a bisphosphonate that targets bone resorption. It works by inhibiting osteoclast-mediated bone resorption, which helps reduce bone metastases and related complications in cancer patients.
Zometa is developed by Novartis AG, a global healthcare company. Novartis is listed on the stock exchange under the ticker symbol NVS.
Zometa is in Phase 2 clinical development for nasopharyngeal cancer. It has completed one Phase 2 trial in this indication, and the drug remains investigational for this use.
Zometa has been studied in a completed Phase 2 trial with the identifier NCT00697619. This trial evaluated the efficacy of Zometa in treating bone metastases in patients with stage IV nasopharyngeal cancer and enrolled 60 participants in China.
Zometa is the brand name for zoledronic acid, a bisphosphonate medication. In the context of nasopharyngeal cancer, Zometa is being investigated for its potential to treat bone metastases in this patient population.